The British paper, owned by Pearson, plans to launch a single global print edition starting in the first half of 2014, which will result in closing of the multiple editions that are updated throughout the night for readers in various countries where it was distributed.
With breaking news published real-time on FT.com, the combined edition -- which could be a single section product -- will contain more pre-planned stories and the articles that first appear on the website.
"The 1970s-style newspaper publishing process ��making incremental changes to multiple editions through the night ��is dead," wrote FT editor Lionel Barber in a memo to staff that was published on its website Wednesday.
Top 5 Financial Stocks To Buy For 2015: Novo Nordisk A/S (NVO)
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes care segment covers insulins, oral antidiabetic drugs, and other protein-related products and projects comprising glucagon and protein-related delivery systems, as well as GLP-1 analogue. The Biopharmaceuticals segment provides products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation therapy. Its products are marketed and distributed through subsidiaries, distributors, and independent agents in 180 countries. Novo Nordisk A/S has a collaboration agreement with Archimedes, Inc. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Advisors' Opinion:- [By Stephen Simpson, CFA]
Lexicon announced Tuesday morning that its small (30 pts) proof-of-concept study of '4211 in type 2 diabetics with moderate-to-severe renal impairment was a success. The company didn't offer up much information, other than to say that the company met its primary endpoint of statistically significant glucose reduction in patients with stage three or four kidney disease. The company also noted that the drug led to elevated levels of GLP-1 - a significant hormone in glucose control, and the focus of Novo Nordisk's (NVO) very successful Victoza GLP-1 agonist.
- [By Damian Illia]
In the past, other inhaled insulins have not been very successful. In 2006, Pfizer (PFE) launches Exubera, the first FDA approved inhaled insulin. Pfizer stopped marketing the drug in October 2007 as it only had made $12 million in sales in the first three quarters of that year. Other companies then also decided to discontinue their own inhaled insulin programs. This means that even if Afrezza clears its way into FDA approval and makes it into the market, it will be hard to convince physicians to prescribe this drug over other existing and "safer" ones. Also, it will have to compete with the market leaders, such as Novo Nordisk (NVO) which derives 78 percent of total sales from diabetes care products.
- [By Bryan Murphy]
The advent of stem cell biotechnology has put several diseases and ailments in the crosshairs... cancer, multiple sclerosis, arthritis, and even brain injuries, just to name a few. There are no limits to what cell-based therapies could do, however, with the right ingenuity and know-how. That's how a small cap, off-the-radar company called BioRestorative Therapies, Inc. (OTCBB:BRTX) may be about to make life much more difficult for bigger diabetes players like Johnson & Johnson (NYSE:JNJ) and Novo Nordisk A/S (NYSE:NVO).
- [By Sean Williams]
The end of the week didn't bring good tidings for shareholders of Novo Nordisk (NYSE: NVO ) , which, according to a report from BioCentury, received a second complete response letter (i.e., a rejection letter) from the FDA for its recombinant Factor XIII therapy to treat a form of hemophilia. According to the report, the rejection is based on unresolved issues at Novo Nordisk's manufacturing facility and merely adds to a series of struggles the company has had with regard to advancing its hemophilia-related pipeline. As you might expect, Novo Nordisk is working with the FDA to resolve this issue as quickly as possible.�
5 Best Diversified Bank Stocks To Invest In Right Now: Curtiss-Wright Corporation (CW)
Curtiss-Wright Corporation, together with its subsidiaries, designs, manufactures, and overhauls precision components and systems. It operates in three segments: Flow Control, Motion Control, and Metal Treatment. The Flow Control segment designs, manufactures, and distributes engineered products, including valves, pumps, motors, generators, instrumentation, shipboard systems, and control electronics that manage the flow of liquids and gases, generate power, provide electronic operating systems, and monitor or provide critical functions for naval defense, power generation, oil and gas, and general industrial markets. The Motion Control segment designs, develops, manufactures, and maintains mechanical actuation and drive systems, specialized sensors, motors, electronic controller units, and embedded computing components and control systems for ground defense, aerospace defense, commercial aerospace, and general industrial markets. The Metal Treatment segment provides metallu rgical processing services comprising shot peening, laser peening, specialty coatings and heat treating for commercial and defense aerospace, oil and gas, power generation, automotive, transportation, construction equipment, and miscellaneous metal working industries. The company operates primarily in the United States, the United Kingdom, and Canada. Curtiss-Wright Corporation was founded in 1929 and is headquartered in Parsippany, New Jersey.
Advisors' Opinion:- [By Shauna O'Brien]
On Monday, Curtiss-Wright Corp. (CW) announced that it has completed its acquisition of Arens Controls, LLC for $98 million.
The newly acquired business will operate under CW’s Controls segment. David C. Adams, President and CEO of CW noted: “The acquisition of Arens complements our previous acquisitions of Williams Controls and PG Drives, further strengthening and growing Curtiss-Wright’s existing industrial controls business.”
“This is another step toward our vision of being the supplier of choice for operator control subsystems and critical drivetrain components in specialty vehicles. As a leading designer and manufacturer of critical vehicle controls technologies, Arens’ complementary products and long-standing customer relationships position Curtiss-Wright for increased penetration within the commercial and off-road vehicle markets. Additionally, this acquisition allows us to leverage our global manufacturing footprint to create margin expansion opportunities,” Adams added.
Curtiss-Wright shares were down 46 cents, or 1.00%, during Monday morning trading. The stock is up 39% YTD.
5 Best Diversified Bank Stocks To Invest In Right Now: Chimera Investment Corporation (CIM)
Chimera Investment Corporation operates as a real estate investment trust (REIT) in the United States. The company, through its subsidiaries, invests in residential mortgage-backed securities (RMBS), residential mortgage loans, commercial mortgage loans, real estate-related securities, and other asset classes. Its targeted asset classes include agency or non-agency RMBS; prime, jumbo prime, and Alt-A mortgage loans; first or second lien loans secured by multifamily properties, mixed residential or other commercial properties, retail properties, office properties, or industrial properties; and asset-based securities (ABS), including commercial mortgage-backed securities, debt and equity tranches of collateralized debt obligations, and consumer and non-consumer ABS. The company has elected to be treated as a REIT for federal income tax purposes and would not be subject to income tax, if it distributes at least 90% of its REIT taxable income to its share holders. Chimera Inve stment Corporation was founded in 2007 and is based in New York, New York.
Advisors' Opinion:- [By John Maxfield]
"Nepotism has never been unknown in American banking," Martin Mayer wrote in The Greatest-Ever Bank Robbery, his 1990 book about the savings-and-loan crisis. While Mayer was referring to American Continental, the notoriously corrupt holding company run into the ground by the infamous Charles Keating in the 1980s, his point rings true today in the case of Annaly Capital Management (NYSE: NLY ) and its publicly traded portfolio company Chimera Investment (NYSE: CIM ) .
- [By John Maxfield]
Well, it just so turns out that there is. And Annaly Capital Management (NYSE: NLY ) , the parent company in our nonhypothetical tale, has figured out how -- for the record, the publicly traded subsidiary is Chimera Investment Management (NYSE: CIM ) .
- [By Selena Maranjian]
Appaloosa Management reduced its stake in companies such as Chimera Investment (NYSE: CIM ) and Valero Energy (NYSE: VLO ) . Mortgage REIT Chimera Investment recently yielded 10.9%, but it may become less attractive if Congress cancels favorable tax treatment for REITs. Chimera has taken on more risk than many of its brethren, and has had some trouble filing reports on time. Some still like its prospects, though, while others question its hefty management fees.
5 Best Diversified Bank Stocks To Invest In Right Now: Amira Nature Foods Ltd (ANFI)
Amira Nature Foods Ltd., incorporated on February 20, 2012, is a provider of packaged Indian specialty rice, with sales in over 40 countries. It generates the majority of its revenue through the sale of Basmati rice, a long-grain rice grown only in certain regions of the Indian sub-continent. The Company sells its products, primarily in emerging markets, through a distribution network. It sells its Amira brand in more than 25 countries. The Company sells its Amira branded products to Indian retailers such as Bharti Wal-Mart, Big Bazaar, Metro Cash & Carry, Spar, Spencer's Retail, Star Bazaar (Tesco in India) and Total and retailers, such as Carrefour, Costco, Jetro Restaurant Depot, Lulu's and Smart & Final, and through the foodservice channel. It participates across the entire rice supply chain from the procurement of paddy to its storage, aging, processing into rice, packaging, distribution and marketing. In June 2013, the Company announced that it has launched Amira branded products in the United Kingdom. In January 2014, Amira Nature Foods Ltd acquired Basmati Rice GmbH.
The Company operates an automated and integrated processing and milling facility that is located in the vicinity of the key Basmati rice paddy producing regions of northern India. The facility spans a covered area of 310,221 square feet, with a processing capacity of 24 metric tons of paddy per hour. During the year ended March 31, 2012, 34% of its revenue was derived from sales in India, and 50.3% was derived from sales in the Europe, Middle East and Africa region, or EMEA, 14.3% was derived from sales in the Asia Pacific region, and 1.4% was derived from sales in North America.
Advisors' Opinion:- [By Will Ashworth]
Amira Nature Foods�(ANFI) went public last October at $10 per share — and now the stock is trading around 40% higher than that offer price. Compared to IPOs in general, however, the past year’s been anything but smooth. ANFI dropped 19% on its first day of trading and didn’t rise above its offering price until early September.
- [By Tom Bishop]
Steve Halpern: One of your recent recommendations is a company that, really, was probably unknown to most investors. It's called Amira Nature Foods (ANFI) , which is a maker of premium rice. Can you tell us briefly about that?
- [By Roberto Pedone]
A consumer goods player that's starting to trend within range of triggering a big breakout trade is Amira Nature Foods (ANFI), a global provider of packaged Indian specialty rice, with sales in over 40 countries. This stock has been in play with the bulls over the last three months, with shares up 25%.
If you take a look at the chart for Amira Nature Foods, you'll notice that this stock has been uptrending strong for the last five months, with shares soaring higher from its low of $7.44 to its recent high of $17.41 a share. During that uptrend, shares of ANFI have been making mostly higher lows and higher highs, which is bullish technical price action. Shares of ANFI have started to break out above some key near-term overhead resistance levels today at $15.92 to $16.25 a share. That move is quickly pushing shares of ANFI within range of triggering another big breakout trade.
Traders should now look for long-biased trades in ANFI if it manages to break out above its all-time high of $17.41 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 226,387 shares. If that breakout triggers soon, then ANFI will set up to enter new all-time-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $25 to $27 a share.
Traders can look to buy ANFI off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $15.03 a share or around more key near-term support at $14.72 a share. One could also buy ANFI off strength once it starts to clear $17.41 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
No comments:
Post a Comment